Last update Aug. 17, 2019

Itopride Hydrochloride

Low Risk

Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Derived from benzamide with properties similar to metoclopramide.
Indicated in chronic gastritis and dyspepsia.
Oral administration in 3 daily doses.

Since the last update we have not found published data on its excretion in breastmilk.

Its high plasma protein binding (Domínguez 2012) makes it unlikely to transfer into breastmilk in significant amounts.

It has very few bibliographical references, and is sold in few countries.

Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in cases of prematurity.

Alternatives

  • Domperidone ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Metoclopramide ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Itopride Hydrochloride in other languages or writings:

Group

Itopride Hydrochloride belongs to this group or family:

Tradenames

Main tradenames from several countries containing Itopride Hydrochloride in its composition:

Pharmacokinetics

Variable Value Unit
Molecular weight 395 daltons
Protein Binding 96 %
pKa 14.71 -
Tmax 0.5 - 0.75 hours
2.95 - 5.7 hours

References

  1. Yoon S, Lee H, Kim TE, Lee S, Chee DH, Cho JY, Yu KS, Jang IJ. Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteers. Drug Des Devel Ther. 2014 Jan 15;8:123-8. Abstract
  2. Dominguez. Itoprida (Aflusan). Ficha técnica. 2012 Full text (in our servers)
  3. Cho KJ, Cho W, Cha KH, Park J, Kim MS, Kim JS, Hwang SJ. Pharmacokinetic and bioequivalence study of itopride HCl in healthy volunteers. Arzneimittelforschung. 2010;60(3):137-40. Abstract

Total visits

5,549

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM